CGC

Canopy Growth Corporation

Fundamental data last updated:August 30, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

County of HQ

CA

Next Earnings Date

Pending Announcement

Business Summary

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

 


Analyze CGC on TradingView

VALUATION

P/E

-1.16

Market Cap ($M USD)

$468.38M

Forward P/E

50.77

PEG

0.50

PRICE TO SALES

0.99

PRICE TO BOOK

0.69

EV / EBITDA

-0.71

5-Year Average P/E

Free Cash Flow Yield

-31.56%

DCF Value

$-7.50

Graham Number

N/A

Price to FCF

-3.17

EV to FCF

-2.03

Earnings Yield

-62.59%

FCF Yield

-31.56%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.95

Next Year EPS Growth Estimate

$0.02

Next Year Revenue Growth Estimate

$330.79M

Return on Equity (ROE)

-52.88%

FREE CASH FLOW

Operating Margin

-25.46%

Debt-to-Equity

0.72

Piotroski F-Score

4

Altman Z-Score

-13.19

Return on Invested Capital (ROIC)

-7.03%

Current Ratio

5.34

Quick Ratio

4.26

Net Debt to EBITDA

0.40

Interest Coverage

-1.72

Gross Profit margin

24.13%

FCF PER SHARE

$-0.25

REVENUE PER SHARE

$0.81

Analyze CGC on TradingView

Gainseekers Quantitative Analysis

Summary

Canopy Growth Corporation’s financial health paints a grim picture. The stock has been trading well below its DCF value, indicating potential mispricing, yet the negative earnings yield and abysmal Altman Z-score suggest significant financial distress. With a Forward P/E of over 50, the market seems overly optimistic about future earnings, despite the company’s current inability to generate profits. The negative ROIC and operating margins further highlight management’s struggle to create value, raising red flags for any prudent investor.

AI Exposure / Tech Reliance

Operating in the healthcare sector, particularly in drug manufacturing, Canopy Growth is positioned to leverage AI advancements in drug discovery and personalized medicine. However, its current financial instability may hinder its ability to invest in cutting-edge technologies. The company must navigate these challenges to remain competitive in a rapidly evolving industry.

The Bull Case

For the optimistic investor, Canopy Growth offers a tantalizing prospect. The forward PEG ratio below 1 suggests undervaluation relative to expected growth, while a Piotroski F-Score of 4 indicates some financial stability. Despite negative free cash flow, the company's substantial sales growth forecast could signal future profitability. The current ratio above 5 suggests strong liquidity, providing a buffer against short-term liabilities and potential for strategic investments.

The Bear Case

Yet, the bear case is compelling. Canopy Growth's negative EPS and operating margin underscore its inability to turn sales into profits. The Altman Z-score signals a high risk of bankruptcy, and the negative EV to EBITDA ratio reflects operational inefficiencies. Trading near its 52-week low, the stock's technical position is weak, and the lack of dividend yield offers little incentive for income-focused investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$14.47

Institutional Ownership %

1-Year Beta

2.39

Insider Buying % (6 Mo)

Distance to 52-Week High

116.38%

Distance to 52-Week Low

23.27%

EARNINGS SURPRISE %

-233.33%

50-DAY SMA

$1.07

200-DAY SMA

$1.22

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.